Axsome Therapeutics Statistics
Share Statistics
Axsome Therapeutics has 48.46M shares outstanding. The number of shares has increased by 2.3% in one year.
| Shares Outstanding | 48.46M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.96% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 39.61M |
| Failed to Deliver (FTD) Shares | 410 |
| FTD / Avg. Volume | 0.07% |
Short Selling Information
The latest short interest is 6.52M, so 13.45% of the outstanding shares have been sold short.
| Short Interest | 6.52M |
| Short % of Shares Out | 13.45% |
| Short % of Float | 16.45% |
| Short Ratio (days to cover) | 12.16 |
Valuation Ratios
The PE ratio is -15.11 and the forward PE ratio is -46.06.
| PE Ratio | -15.11 |
| Forward PE | -46.06 |
| PS Ratio | 13.36 |
| Forward PS | 3.9 |
| PB Ratio | 18.93 |
| P/FCF Ratio | -24.82 |
| PEG Ratio | n/a |
Enterprise Valuation
Axsome Therapeutics Inc. has an Enterprise Value (EV) of 3.42B.
| EV / Earnings | -14.28 |
| EV / Sales | 12.62 |
| EV / EBITDA | -15.18 |
| EV / EBIT | -14.73 |
| EV / FCF | -23.45 |
Financial Position
The company has a current ratio of 3.63, with a Debt / Equity ratio of 0.93.
| Current Ratio | 3.63 |
| Quick Ratio | 3.52 |
| Debt / Equity | 0.93 |
| Total Debt / Capitalization | 48.25 |
| Cash Flow / Debt | -0.81 |
| Interest Coverage | -35.93 |
Financial Efficiency
Return on equity (ROE) is -1.25% and return on capital (ROIC) is -61.68%.
| Return on Equity (ROE) | -1.25% |
| Return on Assets (ROA) | -0.41% |
| Return on Capital (ROIC) | -61.68% |
| Revenue Per Employee | 445.80K |
| Profits Per Employee | -394.13K |
| Employee Count | 607 |
| Asset Turnover | 0.46 |
| Inventory Turnover | 1.72 |
Taxes
| Income Tax | 960.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 5.05% in the last 52 weeks. The beta is 1.25, so Axsome Therapeutics 's price volatility has been higher than the market average.
| Beta | 1.25 |
| 52-Week Price Change | 5.05% |
| 50-Day Moving Average | 92.84 |
| 200-Day Moving Average | 84.32 |
| Relative Strength Index (RSI) | 39.67 |
| Average Volume (20 Days) | 575.17K |
Income Statement
In the last 12 months, Axsome Therapeutics had revenue of 270.60M and earned -239.24M in profits. Earnings per share was -5.27.
| Revenue | 270.60M |
| Gross Profit | 244.53M |
| Operating Income | -231.82M |
| Net Income | -239.24M |
| EBITDA | -224.99M |
| EBIT | -231.82M |
| Earnings Per Share (EPS) | -5.27 |
Balance Sheet
The company has 386.19M in cash and 186.37M in debt, giving a net cash position of 199.82M.
| Cash & Cash Equivalents | 386.19M |
| Total Debt | 186.37M |
| Net Cash | 199.82M |
| Retained Earnings | -835.57M |
| Total Assets | 561.46M |
| Working Capital | 282.93M |
Cash Flow
In the last 12 months, operating cash flow was -145.08M and capital expenditures -582.00K, giving a free cash flow of -145.66M.
| Operating Cash Flow | -145.08M |
| Capital Expenditures | -582.00K |
| Free Cash Flow | -145.66M |
| FCF Per Share | -3.21 |
Margins
Gross margin is 9.04K%, with operating and profit margins of -8.57K% and -8.84K%.
| Gross Margin | 9.04K% |
| Operating Margin | -8.57K% |
| Pretax Margin | -8.81K% |
| Profit Margin | -8.84K% |
| EBITDA Margin | -83.15% |
| EBIT Margin | -85.67% |
| FCF Margin | -53.83% |
Dividends & Yields
AXSM does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -6.09% |
| FCF Yield | -3.48% |
Analyst Forecast
The average price target for AXSM is $122, which is 41.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $122 |
| Price Target Difference | 41.1% |
| Analyst Consensus | Buy |
| Analyst Count | 14 |
Scores
| Altman Z-Score | 2.18 |
| Piotroski F-Score | 3 |